Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B

References

• Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–10.
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–1273.e1.
   Web of Science ®Google Scholar
• Song P, Gao J, Inagaki Y, et al. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in japan and china. Liver Cancer. 2013;2(1):31–39.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel R, et al. Global cancer statistics, 2012. CA: Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Zheng X, Wang J, Yang D. Antiviral therapy for chornic hepatitis B in China. Med Microbiol Immunol. 2015;204:115–120.
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. [The guideline of prevention and treatment for chronic hepatitis B (2010 version)]. Zhonghua Gan Zang Bing Za Zhi. 2011;19:13–24.
   PubMedGoogle Scholar
• Terrault NA, Bzowej NH, Chang K-M, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–283.
   PubMed Web of Science ®Google Scholar
• Park JW, Kwak KM, Kim SE, et al. Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients. BMC Gastroenterol. 2017;17:39.
   PubMed Web of Science ®Google Scholar
• Yu R, Fan R, Hou J. Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China. Front Med. 2014;8:135–144.
   Web of Science ®Google Scholar
• Chen EQ. Current trends of combination therapy in chronic hepatitis B management in China. Arch of Hepat Res. 2015;1:1–4.
   Google Scholar
• Chotiyaputta W, Peterson C, Ditah FA, et al. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Heptaol. 2011;54:12–18.
   PubMed Web of Science ®Google Scholar
• Ha NB, Garcia RT, Trinh HN, et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci. 2011;56:2423–2431.
   Web of Science ®Google Scholar
• Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893.
   PubMed Web of Science ®Google Scholar
• Zhang Q-Q, An X, Liu Y-H, et al. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J. 2011;8:72.
   PubMed Web of Science ®Google Scholar
• Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593–1608.
   PubMed Web of Science ®Google Scholar
• Cooke GS, Main J, Thursz MR. Treatment for hepatitis B. BMJ. 2010;340:b5429.
   Google Scholar
• Chotiyaputta W, Hongthanakorn C, Oberhelman K, et al. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice virological breakthroughs. J Viral Hepat. 2012;19:205–212.
   PubMed Web of Science ®Google Scholar
• Giang L, Selinger CP, Lee AU. Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires. World J Hepatol. 2012;4:43–49.
   PubMedGoogle Scholar
• Van Vlerken LG, Arends P, Lieveld FI, et al. Real life adherence of chronic hepatitis B patients to entecavir treatment. Dig Liver Dis. 2015;47:577–583.
   Google Scholar
• Wang S, Liu L, Li L, et al. Comparison of Chinese inpatients with different types of medical insurance before and after the 2009 healthcare reform. BMC Health Serv Res. 2014;14:443.
   PubMed Web of Science ®Google Scholar
• Morisky DE, Ang A, Krousel-Wood M, et al.Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10:348–354.
   PubMed Web of Science ®Google Scholar
• Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication nonadherence: response to authors. J Clin Epidemiol. 2011;64:255–257.
   PubMed Web of Science ®Google Scholar
• Krousel-Wood M, Islam T, Webber LS, et al. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009;15:59–66.
   PubMed Web of Science ®Google Scholar
• Wojcik K, Piekarska A, Jalonowska E. Adherence to antiviral therapy in HIV or HBV-infected patients. Przegl Epidemiol. 2016;70:27–32.
   Google Scholar
• Malespin M, Wong S, Siqueira F, et al. Barriers to treatment of hepatitis B in an urban Chinatown community.J Clin Gastroenterol. 2012;46:e66–e70.
   Web of Science ®Google Scholar
• Allard N, Dev A, Dwyer J, et al. Factors associated with poor adherence to antiviral treatment for hepatitis B. J Viral Hepat. 2017;24:53–58.
   Web of Science ®Google Scholar
• Lieveld FI, van Vlerken LG, Siersema PD, et al. Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. Ann Hepatol. 2013;12:380–391.
   PubMed Web of Science ®Google Scholar
• Meng Q, Zhang J, Yan F, et al. One country, two worlds – the health disparity in China. Glob Public Health. 2012;7:124–136.
   PubMed Web of Science ®Google Scholar
• Wallace J, Pitts M, Liu C, et al. Needs assessment of viral hepatitis - China. Melbourne: Australian Research Centre in Sex, Health and Society, La Trobe University; 2015. Available from: http://www.nohep.org/wp-content/uploads/2016/07/Needs-Assessment-of-People-Living-with-Viral-Hepatitis-China.pdf
   Google Scholar
• Johnson J, Stoskopf C, Shi L. Comparative health systems: a global perspective. Burlington: Jones & Bartlett Learning; 2017. p. 445.
   Google Scholar
• Wu W, Zhu Y, Yu C, et al. Clinical features of treatment-naive patients with hepatitis B virus infection: A community-based survey from high- and intermediate-hepatitis B endemicity regions in Southeast China. Medicine (Baltimore). 2017;96:e6660.
   Web of Science ®Google Scholar
• Xu K, Watanabe-Galloway S, Rochling FA, et al. Practice, knowledge, and barriers for screening of hepatocellular carcinoma among high-risk Chinese patients. Ann Global Health. 2017;83:281–292.
   Web of Science ®Google Scholar
• Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother. 2011;9:11–23.
   PubMed Web of Science ®Google Scholar
• Benner JS, Chapman RH, Petrilla AA, et al. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm. 2009;66:1471–1477.
   PubMed Web of Science ®Google Scholar
• Marcum ZA, Gellad WF. Medication adherence to multi-drug regimens. Clin Geriatr Med. 2012;28:287–300.
   PubMed Web of Science ®Google Scholar
• Miller TA, DiMatteo MR. Importance of family/social support and impact on adherence to diabetic therapy. Diabetes Metab Syndr Obes. 2013;6:421–426.
   PubMedGoogle Scholar
• Glasgow RE, Toobert DJ. Social environment and regimen adherence among type II diabetic patients.Diabetes Care. 1988;11:377–386.
   PubMed Web of Science ®Google Scholar
• Wang J. Clinical utility of entecavir for chronic hepatitis B in Chinese patients. Drug Des Devel Ther. 2013;8:13–24.
   Web of Science ®Google Scholar
• Toy M, Hutton DW, So SK. Cost-effectiveness and cost thresholds of generic and brand drugs in a national chronic hepatitis B treatment program in China. PLoS One. 2015;10:e0139876.
   Web of Science ®Google Scholar
• Hill A, Gotham D, Cooke G, et al. Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. J Virus Erad. 2015;1:103–110.
   Web of Science ®Google Scholar
• Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J. 2011;26:155–159.
   PubMedGoogle Scholar
• Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol. 2017;9:227–241.
   PubMed Web of Science ®Google Scholar
• Yang T, Wu MC. Discrimination against hepatitis B carriers in China. Lancet. 2011;378:1059.
   Web of Science ®Google Scholar
• Bornstein MH, Jager J, Putnick DL. Sampling in developmental science: situations, shortcomings, solutions, and standards. Dev Rev. 2013;33:357–370.
   PubMed Web of Science ®Google Scholar